Upadacitinib, a Selective JAK1 Inhibitor, for Moderate-Severe Ulcerative Colitis: Adjusting the Top-Down Treatment Algorithm for UC

Jami Kinnucan, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MSc (Epi) discuss “Upadacitinib as Induction and Maintenance Therapy for Moderately to Severely Active Ulcerative Colitis: Results from Three Phase 3, Multicentre, Double-Blind, Randomised Trials,” by Danese S, Vermeire S, Zhou W, et al, published in Lancet [2022; 399: 2113-28].